Royal Bank Of Canada Corbus Pharmaceuticals Holdings, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.11 - $5.46 $174 - $8,659	1,586 Added 5.1%	32,689 $3,000
Q3 2022 Nov 14, 2022	BUY	$0.17 - $5.31 $5,270 - $164,625	31,003 Added 31003.0%	31,103 $5,000
Q2 2022 Aug 15, 2022	SELL	$0.21 - $0.53 $3,399 - $8,579	-16,187 Reduced 99.39%	100 $0
Q1 2022 May 16, 2022	BUY	$0.32 - $0.67 $3,024 - $6,332	9,451 Added 138.25%	16,287 $8,000
Q4 2021 Feb 14, 2022	SELL	$0.6 - $1.11 $3,463 - $6,406	-5,772 Reduced 45.78%	6,836 $4,000
Q3 2021 Nov 15, 2021	SELL	$1.01 - $1.82 $26,758 - $48,219	-26,494 Reduced 67.76%	12,608 $13,000
Q2 2021 Aug 16, 2021	BUY	$1.39 - $2.21 $54,351 - $86,415	39,102 New	39,102 $71,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $2.08B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.